dual agonist glp-1 glucagon Science Behind GLP 1 GIP and Receptor Agonists for Obesity Research | News & Announcements Glucagon-Like Peptide-1 Based Therapies: A

Lebrun LJ, Lenaerts K, Kiers D, Pais de Barros JP, le Guern N, Plesnik J, Thomas C, Bourgeois T, Dejong CHC, Kox M, Hundscheid IHR, Khan NA, Mandard S, Deckert V, Pickkers P, Drucker DJ, Lagrost L, Grober J (2017) Enteroendocrine L cells sense LPS after gut barrier injury to enhance GLP-1 secretion

A minority of users cite slower-than-expected results, often linked to unrealistic comparisons with GLP-1 medications

Users often describe feeling normal again while still experiencing strong appetite suppression

Common issues include: Nausea Diarrhea Stomach cramps Constipation Increased heart rate These gastrointestinal disturbances, such as nausea and cramps, are often linked to slower gastric emptying, a hallmark of these medications

Nicola Magrini, Unit head for Innovation, Evidence synthesis and Clinical research, University Hospital, Bologna, Italy, Co-Chair of the Guidelines Development Group Comments: GLP-1 and inclusion in the essential medicine Mr Deus Mubangizi, Director, Medicines and Health Products Policies and Standards Department, WHO Panel discussion Ms Jeanette Hunter General Primary Health Care at the National Department of Health (NDoH) of South Africa, and Co-Chair of the Guidelines Development Group